Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

Bernard Moss, Miles W. Carroll, Linda S. Wyatt, Jack R. Bennink, Vanessa M. Hirsch, Simoy Goldstein, William R. Elkins, Thomas R. Fuerst, Jeffrey D. Lifson, M. Piatak, Nicholas P. Restifo, Willem Overwijk, Ronald Chamberlain, Steven A. Rosenberg, Gerd Sutter

Research output: Contribution to journalArticlepeer-review

113 Scopus citations


Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-F(ha/np) induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA- SIV(env/gag/pol) greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-βgal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalAdvances in experimental medicine and biology
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates'. Together they form a unique fingerprint.

Cite this